ELAB vs. CUE, ALZN, RNXT, DARE, VYNE, PMN, LPCN, CLNN, EQ, and BIVI
Should you be buying Elevai Labs stock or one of its competitors? The main competitors of Elevai Labs include Cue Biopharma (CUE), Alzamend Neuro (ALZN), RenovoRx (RNXT), Daré Bioscience (DARE), VYNE Therapeutics (VYNE), ProMIS Neurosciences (PMN), Lipocine (LPCN), Clene (CLNN), Equillium (EQ), and BioVie (BIVI). These companies are all part of the "pharmaceutical preparations" industry.
Elevai Labs (NASDAQ:ELAB) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.
Elevai Labs has a net margin of -211.25% compared to Cue Biopharma's net margin of -711.84%. Cue Biopharma's return on equity of -128.30% beat Elevai Labs' return on equity.
22.2% of Elevai Labs shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 7.5% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Cue Biopharma had 8 more articles in the media than Elevai Labs. MarketBeat recorded 9 mentions for Cue Biopharma and 1 mentions for Elevai Labs. Elevai Labs' average media sentiment score of 1.87 beat Cue Biopharma's score of 0.44 indicating that Elevai Labs is being referred to more favorably in the media.
Cue Biopharma received 145 more outperform votes than Elevai Labs when rated by MarketBeat users.
Cue Biopharma has a consensus target price of $5.80, indicating a potential upside of 765.67%. Given Cue Biopharma's higher probable upside, analysts clearly believe Cue Biopharma is more favorable than Elevai Labs.
Elevai Labs has higher earnings, but lower revenue than Cue Biopharma. Elevai Labs is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Cue Biopharma beats Elevai Labs on 11 of the 15 factors compared between the two stocks.
Get Elevai Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elevai Labs Competitors List
Related Companies and Tools
